156 results
To determine the effect of RIPC on MINS in patients after pancreatic sugery.
To assess real world experience with HeartMate PHP post CE Mark approval in supporting patients who are hemodynamically unstable, or at risk of being hemodynamically unstable, while undergoing complex percutaneous coronary interventions (PCI).
The purpose of the study is to examine how the Minicare I-20 fits into the ambulance workflow. Relevant process data of the ambulance workflow was collected (stage 1) looking specifically into chest pain patients. This second stage will focus on…
The objective of the clinical study is to evaluate the incidence of device- and procedure-related safety, efficacy, and efficiency (6-and 12-month outcomes) when using the AcQMap as an imaging and mapping system for ablation of persistent atrial…
The primary objective of this study is to assess the renal safety of CSL112 in subjects with moderate RI and AMI after administration of up to 4 weekly infusions of CSL112.The secondary objectives of the study are:1. To further characterize the…
This study aims at establishing the influence of sampling site on the variability of ACT measurement at the end of coronary angiography or PCI.
The purpose of this investigation is to evaluate decellularized homograft for aortic valve replacement (ARISE AV) rates in comparison to current valve substitutes within a large prospective multicentre surveillance at 6 leading European Centres for…
The objectives of this study are to evaluate the safety and performance of the valve and delivery systems for the treatment of symptomatic moderate to severe degenerative or functional mitral regurgitation in a prohibitively high risk patient…
Area of interest (study setting): Specific aims:Transient triggers and chronic riskfactors (case-crossover and casecontrol)(1) To investigate frequency and strength of association between transient physical andpsychological triggers and early-onset…
Primary objective: to identify intra-individual changes of clinical and biochemical markers of AT characteristics before, and one year after bariatric surgery by:* Determining circulating AT derived biomarkers * Determining local AT biomarkers in…
1. The primary objective is to assess the effects of four 250 mg PC-mAB (also referred to as "3G10") once monthly intravenous injections on monocyte function ex vivo. The secondary objectives are to:1. assess the functional effects of 3G10…
Primary objective: to identify the most important cardiac imaging (ECHO-ST, CT and MRI) and circulating biomarkers of radiation-induced cardiovascular changes arising in the first 2 years after BC RT and to develop Normal Tissue Complication…
To assess the effects of marathon running on changes in cardiac and skeletal muscle structure and function using state of the art MRI techniques, ultra-sensitive biomarker assays and a high resolution 64-lead electrocardiogram.
To prevent vessel damage of the radial artery by using the Cordis Railway sheathless guiding catheter system.
The primary objective of the study is to evaluate the effect of diuretics on right ventricular function and volume properties in patients with symptomatic right heart failure and PH.
The primary objective of Do CHANGE is to develop a health ecosystem for integrated disease management of citizens with high bloodpressure and patients with ischemic heart disease or heart failure. The system will give them access to a set of…
The primary objective of the study is to outline the advantages of LP implantation in TAVI patients who require temporary, and possibly permanent pacing compared to the Standard of Care using TV-TP therapy. We will study whether placement of a LP…
Flecainide is more effective in reducing the amount of PVCs than beta-blocker metoprolol.
The objective of this event-driven trial is to demonstrate superiority of empagliflozin 10 mg versus placebo in patients with symptomatic, chronic HF and preserved ejection fraction (LVEF > 40%) under stable treatment of HF symptoms.
Primary :The primary objective is to evaluate the effect of inclisiran treatment on:* LDL-C levels at Day 510.* Time adjusted percent change in LDL-C levels from baseline after Day 90 up to Day 540 levelsSecondary:The secondary objectives are to…